
Results 1 - 20 of 25 in Clarinex, Desloratadine (generic)
Allergy drug tackles nasal congestion: study
The "second generation" allergy drug desloratadine significantly reduces both the runny nose and congestion of seasonal and persistent allergic rhinitis, a study shows. Comment?
Allergy Drug Tackles Nasal Congestion: Study
The "second generation" allergy drug desloratadine significantly reduces both the runny nose and congestion of seasonal and persistent allergic rhinitis, a study shows. Comment?
Merck completes $41B purchase of Schering-Plough
New Jersey drugmakers Merck & Co. and Schering-Plough Corp. have made their longtime partnership permanent. Comment?
Merck set to close US$41-billion purchase of Schering-Plough
Merck&Co. is set to complete its US$41-billion acquisition of Schering-Plough Corp. Comment?
Merck To Complete $41B Schering-Plough Takeover
Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. Comment?
My boyfriend uses 4 Way nasal spray several times a day and has been 11/02/09 using it for a long time, probably years. Comment?
China allergy drug market report from Research and Markets
Research and Markets has announced the addition of the "China Allergy Drug Market Report 2008" report to their offering. Comment?
Research and Markets: China Allergy Drug Market Report 2008
Statistic data indicate that the Chinese incidence of allergy diseases is as high as 37.3%. The incidences of allergy in the eastern coastal regions are higher than that in the inner land. Comment?
Schering-Plough loses $473M US tax dispute
Drugmaker Schering-Plough Corp. has been denied a $473 million US tax refund by a federal judge who ruled the company made two transactions just to avoid paying taxes on $690 million in profits from overseas subsidiaries. Comment?
Schering Plough loses tax dispute
Drugmaker Schering-Plough Corp. has been denied a $473 million tax refund by a federal judge who ruled the company made two transactions just to avoid paying taxes on $690 million in profits from overseas subsidiaries. Comment?
Differnet brands of levothyrxine may not work the same. simvastatin vs lovastatin, If you get a prescrpition refill and your new pros and cons of lunesta, pills look diffreent, talk with your pharmcaist or dotor.. nexium nebenwirkungen, Do not use this medicaiton more often or for cephalexin capsules 500mg, longer than is prescrbied by your docor. Comment?
If you expeirence any of the follownig less sreious clarinex ingredient, side effcets, cotinue taking Sedlane and talk to your inderal and prozac, docto:r. HIV or AIDS medicaitons.. Ivnega. Comment?
There are no restrictons on food, beveages, or actviities tricor drug, while you are taking this mediction, unless your doctor ambien affects prostate, diects othewrise.. If an overose of Iressa is susected, inderal blood pressure side effects, seek emergeny medcial atteniton or contcat your healthcre proivder xenical generic, immediatly.. levitra ... 1 comment
Multums drug infomration does not enodrse drugs, diagonse patiets nifedipine, or recommend thearpy. Comment?
It is imporatnt to use tamxifen regualrly to get aciphex 20mg dosage, the most beneit. Comment?
The absene of a waring for a given drug motrin 800, or drug combniation in no way should be constued botox pictures before after, to indiacte that the drug or drug combiation is coumadin and keflex, safe, effetive or approprate for any given patint. Comment?
Schering-Plough Announces Resolution Of Litigations On U.S. Marketing Of...
Schering-Plough Corporation today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. Comment?
Schering-Plough Announces Resolution of Litigations on U.S. Marketing ...
Schering-Plough Corporation today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. Comment?
Schering-Plough Settles Lawsuits
Analyst Report ) said it has signed an agreement with Orchid Chemicals & Pharmaceuticals Ltd. Comment?
Orchid Chemicals settles patent row with Schering-Plough
Chennai: Orchid Chemicals & Pharmaceuticals Ltd., announced the settlement of its patent litigation row with Schering-Plough on Wednesday. Comment?